A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 172 participants.
Also called NCT03988920
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 172 participants
- Sponsor
- Registry
-
NCT03988920
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03988920. Non-randomized; no masking; primary purpose treatment. Start 2019-06-15 (actual); primary completion 2021-06-26 (actual). Results posted on 2023-03-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
- Acronym
- NORMALIZE
- Condition
- Hyperphosphatemia
- Condition
- End Stage Renal Disease
- Intervention (Drug)
- Tenapanor
- Intervention (Drug)
- Sevelamer Carbonate
- Lead sponsor
- Ardelyx
Record details
- Record id
cardio:ct-nct03988920- Content hash
d4bf2a49f577a5bf67f38bf8c6eb5b6e167b0a5616c1ec95fa071dc412253b1e